Prestige BioPharma Limited

KSE 950210.KS

Prestige BioPharma Limited EPS (Diluted) for the year ending June 30, 2024: USD -0.40

Prestige BioPharma Limited EPS (Diluted) is USD -0.40 for the year ending June 30, 2024, a -279.45% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

Prestige BioPharma Limited EPS (Diluted) for the year ending June 30, 2023 was USD 0.22, a 108.13% change year over year.
Prestige BioPharma Limited EPS (Diluted) for the year ending June 30, 2022 was USD -2.72, a -2,172.75% change year over year.
Prestige BioPharma Limited EPS (Diluted) for the year ending June 30, 2021 was USD -0.12, a -188.88% change year over year.
Prestige BioPharma Limited EPS (Diluted) for the year ending June 30, 2020 was USD -0.04, a -898.20% change year over year.

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Shares (Basic, Weighted)	Revenue

KSE: 950210.KS

Prestige BioPharma Limited

CEO	Ms. So-Yeon Park
IPO Date	Feb. 9, 2021
Location	Singapore
Headquarters	21 Biopolis Road
Employees	66
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Prestige BioPharma Limited, a biopharmaceutical company, engages in the research, development, and marketing of biosimilars and new antibody therapeutics in the Asia Pacific. The company primarily engages in the development of new and similar antibody drugs for solid tumor, pancreatic cancer, breast cancer, gastric cancer, and arthritis. It is also developing vaccines for COVID-19 virus. The company was incorporated in 2015 and is headquartered in Singapore.

Key trends

Past 5 years